Cory Sago
Chief Executive Officer & Founder Amplitude Therapeutics
Cory Sago is the co-founder and CEO of Amplitude Therapeutics. Previously, he co-founded and was CTO of Guide Therapeutics, a LNP discovery company acquired by Beam Therapeutics in 2021.
Seminars
- What are the future opportunities, promising targets and applications on the horizon for mRNA to achieve commercial success?
- How are recent mRNA and LNP platform acquisitions fueling next generation innovations from science to strategy?
- Linear, circular, self-amplifying, trans-amplifying RNA – Which modality offers the most efficiency?
- With clinical trials moving towards the far East and Australia, what opportunities does this open for the mRNA industry to progress faster to clinical validation?
- Trans-amplifying RNA (taRNA) combines the advantages of modified mRNA and self-amplifying RNAs
- taRNA leads to increased peak expression as compared to modified mRNA at a fraction of the total RNA dose
- Multiple datasets demonstrating the potency, tolerability, and species translatability of taRNA